Kane Biotech Launches Consumer Product Test for an Innovative Shampoo Containing its Patented Anti-Biofilm Technology
December 16 2019 - 4:15PM
Kane Biotech Inc. (TSX-V:KNE) (the “Corporation” or “Kane
Biotech”), a biotechnology company engaged in the research,
development and commercialization of technologies and products that
prevent and remove microbial biofilms, today announced that it has
launched a consumer product test to evaluate the efficacy of its
new shampoo on dermatitis and dandruff.
Recent research has indicated that the
persistence of microbial biofilm may be linked with aggravating the
symptoms associated with atopic dermatitis, seborrheic dermatitis
(also known as eczema) and dandruff. Kane Biotech’s shampoo
consists of coactiv+TM, a patented anti-biofilm formulation, and
contains ingredients approved as safe for human use.
Kane Biotech will ship 300 samples to registered
adult participants in Ontario and Manitoba with moderate-to-severe
atopic dermatitis, seborrheic dermatitis and/or severe dandruff.
Individuals interested in participating in the consumer product
test may register at
https://kanebiotech.com/shampoo-consumer-test/. In addition, the
Corporation plans to promote the consumer test with a Facebook
advertising campaign in January 2020. Shipping of test samples is
expected to commence in February 2020.
“In the U.S., the anti-dandruff shampoo market
alone is estimated at $3 billion per year, while some 31.6 million
individuals have some form of eczema,” stated Marc Edwards, CEO of
Kane Biotech. “We have anecdotal evidence that indicates our
shampoo offers individuals suffering from these conditions an
effective treatment option without requiring any harsh ingredients
such as coal tar, ketoconazole or selenium sulfide. We are looking
forward to the feedback we receive from this expanded group of
consumers.”
“I highly encourage those looking for a solution
to dry, flaking and itching scalps to participate in Kane Biotech’s
consumer product test,” said David Kemp, a long-time Kane Biotech
investor. “As sufferers of these conditions, my family and I tried
this shampoo, and nothing has worked better. I’m delighted Kane is
moving forward with this trial both as an investor and a
consumer.”
“I want to thank the entire Kane team for
bringing this project together. We already have a number of very
exciting projects in both Animal Health (Oral Care, Skin Care and
Supplements) and Human Health (Chronic Wound Care) on the go that
require our attention, but they have once again demonstrated their
nimbleness by taking on this additional program,” said Mr. Edwards.
“I love this type of project where we take good science and, in
short order, are able to get it into the hands of consumers. The
very small investment of capital associated with this consumer
testing could yield substantial dividends for Kane in the
future.”
About Kane Biotech
Kane Biotech is a biotechnology company engaged
in the research, development and commercialization of technologies
and products that prevent and remove microbial biofilms. The
Corporation has a portfolio of biotechnologies, intellectual
property (56 patents and patents pending, trade secrets and
trademarks) and products developed by the Corporation’s own biofilm
research expertise and acquired from leading research institutions.
StrixNBTM, DispersinB®, Aledex®, bluestemTM, AloSeraTM, coactiv+TM
and Kane® are trademarks of Kane Biotech Inc. The Corporation is
listed on the TSX Venture Exchange under the symbol "KNE".
For more information, please
visit www.kanebiotech.com, or
contact:
Marc Edwards |
|
Chief
Executive Officer |
|
Kane
Biotech Inc. |
|
+1 (514)
910-6991 |
medwards@kanebiotech.com |
|
|
Ray
Dupuis |
|
Chief
Financial Officer |
|
Kane
Biotech Inc. |
|
+1 (204)
298-2200 |
rdupuis@kanebiotech.com |
|
|
Stephen
Kilmer |
|
Investor
Relations |
|
+1 (646)
274-3580 |
skilmer@kanebiotech.com |
|
|
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Caution Regarding Forward-Looking
Information
This press release contains certain statements
regarding Kane Biotech Inc. that constitute forward-looking
information under applicable securities law. These statements
reflect management’s current beliefs and are based on information
currently available to management. Certain material factors or
assumptions are applied in making forward-looking statements, and
actual results may differ materially from those expressed or
implied in such statements. These risks and uncertainties include,
but are not limited to, risks relating to the Company’s: (a)
financial condition, including lack of significant revenues to date
and reliance on equity and other financing; (b) business, including
its early stage of development, government regulation, market
acceptance for its products, rapid technological change and
dependence on key personnel; (c) intellectual property including
the ability of the Company to protect its intellectual property and
dependence on its strategic partners; and (d) capital structure,
including its lack of dividends on its common shares, volatility of
the market price of its common shares and public company costs.
Further information about these and other risks and uncertainties
can be found in the disclosure documents filed by the Company with
applicable securities regulatory authorities, available at
www.sedar.com. The Company cautions that the foregoing list of
factors that may affect future results is not exhaustive.
Kane Biotech (TSXV:KNE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kane Biotech (TSXV:KNE)
Historical Stock Chart
From Sep 2023 to Sep 2024